Finerenone (Kerendia)

Details

Finerenone (brand name Kerendia; Bayer) is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA). Unlike steroidal MRAs (spironolactone, eplerenone), finerenone has greater MR selectivity with no off-target binding to androgen, glucocorticoid, or progesterone receptors — reducing sex hormone-related adverse effects. It has a shorter half-life and no active metabolites. Initially approved for CKD with type 2 diabetes (FIDELIO-DKD, FIGARO-DKD); FINEARTS-HF (NEJM 2024) established its benefit in HFmrEF/HFpEF; FIND-CKD (NEJM 2026) extends evidence to non-diabetic CKD, establishing finerenone as a three-indication drug (diabetic CKD, non-diabetic CKD, HFmrEF/HFpEF).

Key Facts

Mechanism of Action

• Blocks the mineralocorticoid receptor, reducing aldosterone-mediated sodium retention, fluid overload, sympathetic activation, cardiac and renal fibrosis, and inflammation. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
• Greater MR selectivity vs spironolactone → no androgenic side effects (gynecomastia, sexual dysfunction). (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
• Distinct physicochemical properties from steroidal MRAs: non-steroidal scaffold, no active metabolites, shorter half-life. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)

Dosing and Administration

• HF with LVEF ≥40%: Individualized based on eGFR and potassium; maximum 20 mg OD (eGFR ≥60) or 40 mg OD (eGFR ≥25 to <60).
• Requires regular monitoring of serum potassium and renal function.
• Contraindicated when K+ >5 mmol/L at initiation; close monitoring essential. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)

Clinical Trials

FINEARTS-HF (HFmrEF/HFpEF; NEJM 2024)

• Phase 3 double-blind RCT; n=6,001; 654 sites; 37 countries; median 32 months.
• Primary composite (total worsening HF events + CV death): Rate ratio 0.84 (95% CI 0.74–0.95; P=0.007) — first MRA to achieve a positive primary endpoint in HFmrEF/HFpEF.
• Total worsening HF events (secondary): Rate ratio 0.82 (95% CI 0.71–0.94; P=0.006).
• CV death: HR 0.93 (95% CI 0.78–1.11) — NOT significant.
• All-cause death: HR 0.93 (95% CI 0.83–1.06) — NOT significant.
• KCCQ total symptom score: +1.6 points improvement (95% CI 0.8–2.3; P<0.001) — statistically significant but below 5-point MCID.
• NYHA functional class improvement: OR 1.01 (95% CI 0.88–1.15) — NOT significant.
• Kidney composite: HR 1.33 (95% CI 0.94–1.89) — NOT significant; numerically higher.
• Hyperkalemia (K+ >6 mmol/L): 3.0% vs 1.4%; no deaths; 0.5% vs 0.2% hospitalizations.
• Hypokalemia: Reduced with finerenone.
• Benefit consistent in patients on/off baseline SGLT2 inhibitors. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)

CKD + Type 2 Diabetes Trials

• FIDELIO-DKD (NEJM 2020): Finerenone reduced kidney failure and disease progression in CKD + T2DM. eGFR decline 0.7 ml/min/1.73m²/year slower vs placebo.
• FIGARO-DKD (NEJM 2021): Finerenone reduced CV events in CKD + T2DM.
• FIDELITY pooled analysis (Eur Heart J 2022): Composite kidney and CV outcomes consistently improved.
• These data supported finerenone's initial approval for CKD with T2DM.

FIND-CKD — Non-Diabetic CKD (NEJM 2026) — LANDMARK

• Phase 3 double-blind RCT; n=1,584; 32 months; non-diabetic CKD (eGFR 25–<90; UACR 200–3500 mg/g; on RAS inhibitor).
• Primary outcome (total eGFR slope): −3.3 vs −4.0 ml/min/1.73m²/year; difference 0.7 (95% CI 0.3–1.1; P<0.001).
• Composite kidney/CV events: HR 0.77 (95% CI 0.60–0.99; P=0.04); 4.7 vs 5.8 events/100 person-years.
• Composite kidney outcome: HR 0.78 (95% CI 0.60–1.01; P=0.06) — narrowly missed significance.
• Composite CV outcome: HR 0.60 (95% CI 0.27–1.33) — not significant (underpowered).
• UACR reduction at month 6: −41.3% vs −9.1% (relative difference 35.4%); 56.0% vs 24.4% achieved ≥30% UACR reduction (OR 3.99).
• Hyperkalemia: Any 17.0% vs 13.3%; K⁺ >6.0: 4.3% vs 2.3%; hospitalization 0.9% vs 0.6%; permanent discontinuation 1.5% vs 0.1%.
• eGFR effect: Acute eGFR increase with finerenone at month 3 (+1.2 ml/min/1.73m² vs placebo; opposite to SGLT2i acute dip) → total eGFR slope may underestimate true chronic benefit.
• SGLT2i background: 17% at baseline; efficacy consistent regardless of SGLT2i use.
• Clinical significance: First trial establishing finerenone's kidney protection in non-diabetic CKD — extends the drug's evidence base beyond diabetes. Effect magnitude (0.7 ml/min/1.73m²/year) identical to that observed in diabetic CKD (FIDELIO-DKD) and comparable to RAS inhibitors and SGLT2i. (sources/Finerenone-FIND-CKD-NEJM-2026, rating: very high)

Approved Indications

• Chronic kidney disease (CKD) with type 2 diabetes — to reduce risk of kidney disease progression and CV events (FIDELIO-DKD, FIGARO-DKD).
• Non-diabetic CKD — FIND-CKD (NEJM 2026) establishes kidney protection benefit; regulatory approval expected to expand to non-diabetic CKD.
• Heart failure with LVEF ≥40% (HFmrEF and HFpEF) — based on FINEARTS-HF.

Contradictions / Open Questions

• No direct comparison with spironolactone in HFpEF: TOPCAT (spironolactone) vs FINEARTS-HF (finerenone) differ in drug, endpoint methodology (time-to-first vs total events), background therapy, follow-up, and data integrity — it cannot be concluded that finerenone is superior to spironolactone in HFpEF. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
• No mortality benefit despite significant primary endpoint: CV death (HR 0.93; NS) and all-cause death (HR 0.93; NS) were both non-significant in FINEARTS-HF. The primary composite benefit is driven entirely by HF hospitalization reduction — finerenone joins SGLT2i as a class of agents that reduce HF events but not mortality in HFmrEF/HFpEF. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
• Kidney composite numerically worse in HFpEF (HR 1.33) unlike CKD trials: Nephroprotective signal from FIDELIO-DKD/FIGARO-DKD and FIND-CKD does not replicate in HFpEF patients who have low albuminuria and minimal kidney disease burden — the nephroprotective mechanism may be albuminuria/CKD-dependent. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high; sources/Finerenone-FIND-CKD-NEJM-2026 — very high)
• KCCQ improvement is statistically significant but clinically marginal (+1.6 points vs 5-point MCID): The trial was powered for the event-based primary endpoint; the KCCQ improvement is statistically robust but its clinical meaningfulness to individual patients is questionable. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high)
• Additive benefit on top of SGLT2i not established: While benefit was consistent in SGLT2i users (13.6% in FINEARTS-HF, 17% in FIND-CKD at baseline), neither trial was powered to formally confirm additive benefit. The combination of two HF-hospitalization-reducing agents without mortality benefit raises the question of whether combination use offers clinically meaningful incremental gains. (sources/finerenone-hfpef-fineartshf-nejm-2024 — very high; sources/Finerenone-FIND-CKD-NEJM-2026 — very high)
• FIND-CKD: eGFR slope benefit not fully corroborated by clinical kidney outcomes: The primary eGFR slope endpoint was robustly positive (P<0.001) but the kidney composite narrowly missed significance (HR 0.78; P=0.06). While eGFR slope is a validated surrogate, longer follow-up is needed to confirm ESKD reduction in non-diabetic CKD. (sources/Finerenone-FIND-CKD-NEJM-2026 — very high)
• FIND-CKD: CV benefit underpowered: CV composite HR 0.60 (95% CI 0.27–1.33) shows a favorable point estimate but extremely wide confidence intervals. The trial enrolled 1,584 patients — far fewer than dedicated CVOTs. Whether finerenone reduces CV events in non-diabetic CKD remains unproven. (sources/Finerenone-FIND-CKD-NEJM-2026 — very high)
• FIND-CKD: Generalizability limited: Predominantly male, advanced CKD with severe albuminuria, few Black participants, and exclusion of ADPKD/lupus/ANCA vasculitis. The applicability to lower-risk CKD or excluded etiologies is unknown. (sources/Finerenone-FIND-CKD-NEJM-2026 — very high)
• No head-to-head finerenone vs steroidal MRA in CKD: BARACK-D showed >50% spironolactone discontinuation in CKD within 6 months (hyperkalemia + AKI). FIND-CKD showed 19.8% finerenone discontinuation (vs 22.4% placebo — no excess). Finerenone appears better tolerated but direct comparative efficacy is unknown. (sources/Finerenone-FIND-CKD-NEJM-2026 — very high)

Connections

• Related to entities/HFpEF — primary HF target; first MRA with positive primary endpoint in this population
• Related to concepts/Chronic-Kidney-Disease — FIND-CKD establishes finerenone as third pillar of CKD pharmacotherapy regardless of diabetes status
• Related to entities/Heart-Failure — overarching HF framework
• Related to entities/HFrEF — context: steroidal MRAs (RALES, EMPHASIS-HF) established in HFrEF
• Related to concepts/Cardiorenal-Syndrome — divergent nephroprotective signals across HF and CKD populations
• Related to concepts/SGLT2-Inhibitors-in-CKD — complementary CKD pharmacotherapy; potential triple therapy with RASi + SGLT2i + finerenone
• Related to concepts/Mineralocorticoid-Receptor-Antagonists-Post-MI — broader MRA evidence framework
• Related to sources/spironolactone-hfpef-topcat-nejm-2014 — prior MRA attempt in HFpEF

Sources

• sources/finerenone-hfpef-fineartshf-nejm-2024
• sources/Finerenone-FIND-CKD-NEJM-2026